9:30-10:30

Unique Case Presentations of Fabry disease (15 min x 4)

Chair

Aya Narita (Iseikai International General Hospital, Japan)
Masahisa Kobayashi (The Jikei University School of Medicine, Japan)

1) Rescue from sudden ventricular tachycardia and fibrillation using wearable cardioverter-defibrillator in male late-onset Fabry disease patient

Toraaki Okuyama (The Jikei University School of Medicine, Japan)

2) Reduced recurrence of strokes after switching to agalsidase beta in Fabry disease: two case reports

Yoshimi Fujita (The Jikei University School of Medicine, Japan)

3) Clinical Decision Making for Diagnosis and Treatment Initiation in Late Onset Mild Fabry Disease

Kaoru Eto (Tokyo Women’s Medical University Adachi Medical Center, Japan)

4) SGLT2 Inhibitors in Fabry Disease: Evidence of Renoprotection from Case-Based and Clinical Analyses

Hayaki Okamoto (Kobe University Graduate School of Medicine, Japan)

10:30-10:40

Coffee break

10:40-11:20(Co-sponsored by Sanofi)

Chair

Yoshikatsu Eto (Southern Tohoku Institute for Neuroscience / The Jikei University School of Medicine, Japan)

Fabry Disease: Major Advances in Delineation, Diagnosis and Treatment

Robert J. Desnick (Icahn School of Medicine at Mount Sinai, USA）

11:20-12:20(Co-sponsored by Sumitomo Pharma)

Key Points on Fabry Disease and LysoGb3

Chair

Motomichi Kosuga (National Center for Child Health and Development, Japan)
Kazuya Tsuboi (Nagoya Central Hospital, Japan)

1) Biomarkers in Fabry disease: Diagnosis and treatment monitoring

Takahiro Tsukimura (Meiji Pharmaceutical University, Japan) - 30 min

2) A biochemical and pharmacological comparison of three agalsidases approved and used in Japan

Hitoshi Sakuraba (Meiji Pharmaceutical University, Japan) - 30 min

12:30-13:10 Luncheon Seminar (Co-sponsored by JCR)

Chair

Torayuki Okuyama (Saitama Medical University, Japan)

Fabry Disease: Real World Evidence (RWE) of Treatment Outcomes

Roberto Giugliani (Federal University of Rio Grande do Sul, Brazil) - 40 min

13:20-13:50

New Therapy

Chair

Dau-Ming Niu (National Yang Ming Chiao Tung University, Taiwan)

Splicing Modulation Therapy for Taiwanese Cardiac Fabry Disease (GLA c.639+919G>A)

Tomonari Awaya (Osaka Metropolitan University Graduate School of Medicine, Japan) - 30min

13:50-14:30

Chair

Yukio Yuzawa (Vice Chairman, Fujita Academy, Japan)

Second Generation ERTs for Fabry Disease

David G. Warnock (The University of Alabama at Birmingham, USA) - 40 min

14:30-15:40

Organ Specific Outcomes - Kidney, Heart and Brain
1. Renal Problems

Chair

David G. Warnock (The University of Alabama at Birmingham, USA)
Ohsuke Migita (St. Marianna University School of Medicine, Japan)

1) The Evolving Landscape of Fabry Nephropathy

Naoki Nakagawa (Asahikawa Medical University, Japan) - 30 min

2) Increasing knowledge and tools within Fabry nephropathy

Camilla Tøndel (Univ of Bergen, Norway)(Web) - 40 min

15:40-15:50

Coffee break

15:50-17:20(Co-sponsored by Sanofi)

Chair

Hiroyuki Yamakawa (Keio University School of Medicine, Japan)
Katsuya Nakamura (Shinshu University School of Medicine, Japan)

2. Cardiovascular / CNS events

1) Cardiac Involvement in Fabry Disease: Clinical and Pathological Insights

Koji Higuchi (National Institute of Fitness and Sports in Kanoya, Japan)

2) Non-invasive Assessment of Cardiac Involvement in Fabry Disease Using Multimodality Imaging

Kenichi Hongo (The Jikei University School of Medicine, Japan) - 30 min

3) Fabry Disease and Stroke

Alessandro Burlina (St. Bassiano Hospital, Italy) (Web) - 30 min

17:20-18:00

Chair

Takeo Iwamoto (Southern Tohoku Institute for Neuroscience /The Jikei University School of Medicine, Tokyo)
Roberto Giugliani (Federal University of Rio Grande do Sul, Brazil）

LysoGb3 as a Biomarker in Fabry disease

Albina Nowak (University Zurich, Switzerland) - 40 min

18:00-18:40

Chair

Hiroyuki Ida (The Jikei University School of Medicine, Japan)

Antidrug antibodies in Fabry disease: Impact and challenge

Malte Lenders (Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Germany) - 40 min

19:00-21:00

Banquet @ The Prince Park Tower Tokyo 33F

Day 2 / Oct. 3 (SAT)

10:20-12:50 (Co-sponsored by JCR)

Chair

Kimitoshi Nakamura (Kumamoto University Graduate School of Medical Sciences, Japan)
Yin-Hsiu Chien (National Taiwan University, Taiwan)

Newborn screening of Fabry disease: Workshop

Kimitoshi Nakamura / Takaaki Sawada (Kumamoto University Graduate School of Medical Sciences, Japan)

Yin-Hsiu Chien (National Taiwan University, Taiwan)

Dau-Ming Niu (National Yang Ming Chiao Tung University, Taiwan)

Barbara K Burton (Northwestern University, USA)

13:00-14:10 Luncheon seminar (Co-sponsored by Amicus Therapeutics)

Chair

Derralynn A. Hughes (University College London, UK)
Norio Sakai (ISEIKAI International General Hospital, Japan)

Pharmacogical Chaperones: New Frontier

■ Clinical response of migalastat for Fabry disease in Japan

Masahisa Kobayashi (The Jikei University School of Medicine, Japan) - 30 min

■ Alternative disease mechanisms and targets in Fabry disease

Derralynn Hughes (University College of London and Royal Free London NHS Foundation Trust, UK) - 40 min

14:10-14:20

Closing Remark

Masahisa Kobayashi (The Jikei University School of Medicine, Japan)